Shares of GlaxoSmithKline Pharmaceuticals Ltd. slumped to their lowest level in a month on Tuesday after its third-quarter profit tumbled, missing analysts' estimates.
The company's consolidated net profit declined 72.21% year-on-year to Rs 45.72 crore in the quarter ended December, according to an exchange filing. A Bloomberg poll of analysts' estimates pegged net profit at Rs 78.6 crore.
GSK Pharma Q3 Results Highlights (Consolidated, YoY)
Revenue up 0.36% at Rs 805.26 crore (Bloomberg estimate: Rs 970 crore).
Ebitda down 4.66% at Rs 218.06 crore. (Bloomberg estimate: Rs 126.2 crore).
Margin narrows 142 basis point to 27.07% (Bloomberg estimate: 13%).
Net profit down 72.21% at Rs 45.72 crore. (Bloomberg estimate: Rs 78.6 crore).
"While GLXO faced headwinds on account of addition of products under national list of essential medicines, it continues to implement efforts to improve business prospects," said Motilal Oswal in a report.
The brokerage has a 'neutral' rating for the stock with a price target of Rs 2,200 apiece. "We believe that the current valuation adequately captures the upside in earnings," it said.
Shares of the company fell as much as 10.64% to Rs 2,091.05 apiece, the lowest level since Jan. 10. It pared losses to trade 8.1% lower at Rs 2,150.90 apiece as of 10:45 a.m. This compares to a 0.45% advance in the NSE Nifty 50 Index.
It has risen 61.12% in the past 12 months. Total traded volume so far in the day stood at 1.55 times its 30-day average. The relative strength index was at 44.02.
Out of six analysts tracking the company, two maintain a 'buy' rating and four suggest a 'hold', according to Bloomberg data. The average 12-month consensus price target implies a downside of 8.7%.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2024-07/c059fdc9-0bd0-4b9d-b90f-41913fe2b827/Prestige-Estates-Projects-website.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Prestige Estates Raises Rs 5,000 Crore Via QIP; Shares Slip
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-02/aaa1b2b2-b88c-448b-a130-e16b59a057b5/Natco_Pharma_Ltd___Source_Company_Website_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Natco Pharma Q1 Result: Profit Up 59%, Beats Estimates
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-08-10/b6tkl9qz/istockphoto_1277009188_170667a__1_ (1).webp?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Aurobindo Pharma Q1 Result: Profit Rises, In Line With Estimates
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-05/cb30922e-8cae-4516-9ab8-ab762d556b56/img38.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Gland Pharma Shares Near One-Month Low After Q1 Profit Misses Estimates
![timelogo](/images/amp-time.png)